Various platforms have now taken this work forward with the success of extracellular loop peptides, analogues of GAP27, targeting CX43 being successful in clinical trials for patients with ocular conditions including diabetic retinopathy and age related macular degeneration [179,180] (https://ocunexus.com/peptagon). Here, GJA1 is linked to diabetic retinopathy.